구조모아 (StructureMoa)항암 chemical structure spider web
방문Auto-discovered from ClinicalTrials.gov (8 linked trials). 선택한 코호트에서 보고된 효능: ORR 67.3% (ClinicalTrials.gov NCT01294579).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Leukemia
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Recruiting
2026-09-10
Data Confidence · High
Development Signal · Emerging
bispecific T-cell engagers, and chimeric antigen receptor (CAR) T cell
humanized anti-CD20 monoclonal antibody, represents a potential alternative, yet its use in children remains
novel antibody approaches are needed
구조화 데이터
novel antibody approaches are needed
resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed
bispecific T-cell engagers, and chimeric antigen receptor (CAR) T cell
Leukemia · biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease
target cells with low antigen
immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease
resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed
구조화 데이터
xenograft model
mouse, rabbit, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Auto-discovered from ClinicalTrials.gov (8 linked trials). 선택한 코호트에서 보고된 효능: ORR 67.3% (ClinicalTrials.gov NCT01294579).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Leukemia
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Recruiting
2026-09-10
Data Confidence · High
Development Signal · Emerging
bispecific T-cell engagers, and chimeric antigen receptor (CAR) T cell
humanized anti-CD20 monoclonal antibody, represents a potential alternative, yet its use in children remains
novel antibody approaches are needed
구조화 데이터
novel antibody approaches are needed
resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed
bispecific T-cell engagers, and chimeric antigen receptor (CAR) T cell
Leukemia · biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease
target cells with low antigen
immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease
resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed
구조화 데이터
xenograft model
mouse, rabbit, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.